



Herbal medicines for the treatment of otitis media with effusion: Protocol for a systematic review

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-004095
Article Type:	Protocol
Date Submitted by the Author:	22-Sep-2013
Complete List of Authors:	Kim, Yun Hee; Korea Institute of Oriental Medicine, Son, Mi-Ju; Korea Institute of Oriental Medicine, Literature & Informatics Research Division Kim, Young-Eun; Korea Institute of Oriental Medicine, Lee, Hye Won; Korea Institute of Oriental Medicine, Lee, Myeong Soo; Korea Institute of Oriental Medicine,
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Complementary medicine, Ear, nose and throat/otolaryngology
Keywords:	COMPLEMENTARY MEDICINE, OTOLARYNGOLOGY, Herbal medicine < THERAPEUTICS

SCHOLARONE™
Manuscripts

Herbal medicines for the treatment of otitis media with effusion: Protocol for a systematic review

Yun Hee Kim,^{1,†} Mi Ju Son,^{2,†} Young-Eun Kim,² Hye Won Lee,¹ Myeong Soo Lee^{3,*}

¹*Herbal Medicine Research Division,* ²*Literature & Informatics Research Division,* ³*Medical Research Division, Korea Institute of Oriental Medicine, Daejeon, South Korea*

[†] Equally contributed

Running title: Herbal medicines for otitis media with effusion

Keywords: Herbal medicine, complementary and alternative medicine, otitis media, effusion, systematic review, protocol

*Correspondence to:

Myeong Soo Lee, PhD
Medical Research Division,
Korea Institute of Oriental Medicine,
Daejeon, 305-811, South Korea
Tel: 82-(0)42-868-9266
Fax: 82-(0)42-868-9622
E-mail: drmslee@gmail.com

Kim YH: ddyunee@kiom.re.kr
Son MJ: mj714@kiom.re.kr
Kim Y-E: jade2010@kiom.re.kr
Lee HY: hwlee@kiom.re.kr
Lee MS: drmslee@gmail.com

License statement

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non-exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd and its Licensees to permit this article (if accepted) to be published in BMJ Open and any other BMJ PGL products to exploit all subsidiary rights, as set out in our licence (<http://group.bmj.com/products/journals/instructions-for-authors/licence-forms>).

Article focus

- The aim of the proposed systematic review is to analyse trial data concerning the effectiveness of herbal medicines for otitis media with effusion.

Key messages

- This systematic review will be performed using a comprehensive search strategy and will establish the current status of the evidence using unbiased methods.

Strengths and limitations of this study

- The strength of this systematic review is its extensive, unbiased search of various databases without a language restriction.
- The trial screening and data extraction will be conducted independently by two of the authors.

Abstract

Introduction: The purpose of this systematic review is to investigate the effectiveness of herbal medicines for otitis media with effusion (OME) through analysing trial data.

Methods and analysis: Electronic searches of the following eleven databases will be performed: MEDLINE, the Cumulative Index to Nursing and Allied Health Literature (CINAHL), EMBASE, the Allied and Complementary Medicine Database (AMED), the Cochrane Central Register of Controlled Trials (CENTRAL), the China Network Knowledge Infrastructure (CNKI) and five Korean databases [Oriental Medicine Advanced Searching Integrated System (OASIS), DBPIA, Korea-Med, Research Information Service System (RISS) and the Korean Studies Information Service System (KISS)]. The selection of the studies, data abstraction, and validations will be performed independently by two researchers.

Dissemination: The systematic review will be published in a peer-reviewed journal. The review will also be disseminated electronically and in print. Updates of the review will be conducted to inform and guide healthcare practice and policy.

Trial registration number: PROSPERO 2013: CRD42013005430.

Introduction

Description of the condition

Otitis media with effusion (OME) is characterised as the presence of middle-ear effusion without the signs and symptoms of an acute ear infection and a disease course of months until recovery [1-4]. OM affects nearly every child at least once, and approximately 90% of children experience an episode of OME before school age due to incomplete Eustachian tube functioning or inflammation following acute otitis media (AOM) [5 6]. Approximately 35% to 50% of OME patients have chronic or recurrent states. When inadequately treated, OME can cause major functional limitations such as permanent hearing loss, which may delay language, speech and cognitive development [7-9].

Description of the intervention

OME has high socioeconomic consequences, and the annual cost of OME was \$4 billion.[4 5] Patients with OME are treated with antibiotics, antihistamines, steroids and the insertion of ventilation tubes. However, antibiotics and steroids have been suggested to provide only a marginal benefit, and antihistamines are not recommended in systematic reviews.[10-12] A review of randomised controlled trials revealed that the insertion of ventilation tubes reduced the proportion of time spent with effusion compared with watchful waiting. However, ventilation tubes lead to adverse effects, such as tympanosclerosis and tympanic membrane abnormalities [13 14].

How the intervention might work

Currently, many patients who are seeking ways to relieve the symptoms associated with chronic OME or to avoid the side effects of conventional treatment have chosen complementary and alternative medicine (CAM) [15]. Herbal medicine, a part of CAM, is the

1
2
3
4 use of medicinal plants, minerals and animal parts for preventing or treating clinical
5
6 conditions. Many types of herbal medicines are known to have an anti-inflammatory effects
7
8 and have been to reduce swelling and prevent endotoxin-induced OME in experimental
9
10 investigations [16-20].
11
12
13
14

15 ***Why it is important to perform this review***

16
17 Herbal medicine has been approved by the World Health Organization as a therapy for the
18
19 treatment of OME [15 21]. However, no systematic reviews assessing the intervention of
20
21 herbal drugs treatment in OME have been conducted to date. Understanding the effectiveness
22
23 and safety of herbal medicines will allow the appropriate recommendation of an herbal drug
24
25 treatment for patients.
26
27
28
29
30

31 ***Objectives***

32
33 Thus, we will undertake a systematic review to assess the safety and efficacy of herbal drugs
34
35 for the treatment of OME.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Methods

Criteria for considering studies for this review

Types of studies

The review will include randomised controlled trials, including cluster randomised trials. Quasi-randomised trials, in which the group allocation was not purely random but rather determined by a factor such as a birth date, a hospital record number or alternation, will be included. Any trials without parallel comparisons or control groups will be excluded.

Types of participants

The review will include studies evaluating patients who had a diagnosis of OME. The diagnostic criteria for OME should be based on the criteria of the WHO, the American Academy of Pediatrics (AAP) and the American Academy of Otolaryngology and Head and Neck Surgery (AAOHNS), but if necessary, trials for which the definition of OME used by the authors is in question will also be included. We will exclude studies of patients with ventilation tubes present, patients with an anatomical deformity or patients with other chronic immune-compromised states.

Types of interventions

The review will include those trials using herbal medicine alone or as a combined therapy of herbal medicine with a conventional therapy versus the same conventional therapy. Herbal medicine is defined as a single herb, an individually prescribed herbal formula or herbal products extracted from natural herbs. There is no limitation on the number of herbs used, the dosage, the forms of medication or the duration of the treatment. We will include only the oral administration of the medication.

Types of outcome measures

The following outcome measures will be assessed based on analyses of the data obtained in the included trials.

Primary Outcome

Resolution of symptoms or signs (however measured)

Secondary Outcomes

1. Duration of effusion
2. Hearing level
3. Language and speech development
4. Cognitive development
5. Insertion of ventilation tubes
6. New AOM
7. Tympanic membrane sequelae
8. Quality of life
9. Adverse effects likely to be related to treatment

Search methods for identifying the studies

Electronic searches

The electronic searches will be performed using MEDLINE, the Cumulative Index to Nursing and Allied Health Literature (CINAHL), EMBASE, the Allied and Complementary Medicine Database (AMED) and the Cochrane Central Register of Controlled Trials (CENTRAL). We will also search one Chinese database [China Network Knowledge Infrastructure (CNKI)] and five Korean databases [Oriental Medicine Advanced Searching

Integrated System (OASIS), DBPIA, Korea-Med, the Research Information Service System (RISS) and the Korean Studies Information Service System (KISS)].

Searching other resources

The reference lists of review articles and the retrieved articles will be examined to find additional studies. Additional trials will be sought in the meta-Register of Controlled Trials (m RCT) (www.controlled-trials.com/mrct), Clinical trials.gov (www.clinicaltrials.gov) and the WHO International Clinical Trials Registry platform (ICTRP) (<http://apps.who.int/trialsearch/>) for all of which list ongoing trials.

Search strategy

The strategies for searching The Cochrane Library, MEDLINE, and EMBASE databases are presented in Appendix 1. These strategies will be modified for use with other databases.

Data collection and analysis

Selection of studies

Two of the review’s authors (Son MJ and Kim YH) will independently screen the titles and abstracts of the searched studies, perform the study selection and record their decisions on a standard eligibility form. The arbitrator (Lee MS) will decide upon the study selection when a consensus cannot be reached.

Inclusion Criteria

1. In randomised cross-over trials, only the data from the first period will be included to avoid the carry-over effect
2. No language limitation

3. No publication status restriction

Exclusion Criteria

1. Animal experiments
2. Non-randomised clinical trials
3. Case report/series, news items, and letters
4. Qualitative studies

Data extraction and management

Two of the authors (Son MJ and Kim YH) will independently extract the data using a standard data extraction form and resolve disagreements through discussion before analysis. When the reported data are insufficient or ambiguous, two of the authors (Kim YE and Lee HW) will contact the corresponding authors of the clinical trials by e-mail or telephone to request additional information or clarification.

Assessment of risk of bias in the included studies

We will independently assess the risk of bias in the eligible studies according to the criteria in the Cochrane Handbook version 5.1.0, which include random sequence generation, allocation concealment, the blinding of participants and personnel, the blinding of outcome assessment, incomplete outcome data, selective reporting, and other sources of bias [22]. The quality of the study will be classified as low, unclear or high risk of bias. If necessary, we will contact the authors of eligible trials for clarification. Any differences in opinion will be resolved by discussion or arbitration involving a third author.

Assessment of reporting biases

We will prepare funnel plots to assess the reporting biases if sufficient studies are available (at least 10 trials) [23]. However, funnel plot asymmetry is not the same as publication bias; therefore, we will attempt to distinguish the different possible reasons for the asymmetry, such as small-study effects, poor methodological quality and true heterogeneity of the included studies [23 24].

Measurement of the treatment effect

For continuous data, we will use the mean difference (MD) to measure the treatment effect with 95% confidence intervals (CIs). We will convert other forms of data into MDs. In the case of outcome variables with different scales, we will use the standard mean difference (SMD) with 95% CIs. For dichotomous data, we will present the treatment effects as a relative risk (RR) with 95% CIs. We will convert other binary data into the RR form.

Strategy for missing data

We will conduct intention-to-treat analyses that include all of the randomised patients. A carry-forward of the last observed response will be used for patients with missing outcome data. We will seek the individual patient data from the original source or the published trial reports when the individual patient data are unavailable.

Assessment of heterogeneity

If a meta-analysis is possible, we will use the I^2 statistic to quantify the inconsistencies among the included studies. An I^2 value $>50\%$ will be considered indicative of substantial heterogeneity [25]. If heterogeneity is observed, we will conduct subgroup analysis to explore the possible causes [25].

Data synthesis

Data synthesis will be performed using Review Manager (RevMan), Version 5.0, for Windows software. The primary meta-analyses will be performed using random effects models due to the expected inter-trial heterogeneity.

Subgroup analysis and investigation of heterogeneity

If there is a sufficient number of studies, subgroup analyses will be conducted to assess the heterogeneity between the studies, including the following:

1. Type of herbal medicine
2. Type of control
3. Type of age group.

Sensitivity analysis

If an adequate number of studies are available, sensitivity analyses will be performed to determine whether the findings are robust. The following aspects will be considered.

1. Sample size (e.g., more or less than 30 participants in each group)
2. Methodological qualities (e.g., allocation concealment or the blinding of participants/assessors)
3. Analysis-related issues (e.g., processes for handling missing data)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Discussion

Because no primary data collection will be undertaken, no additional formal ethical assessment or informed consent is required. The systematic review will be published in a peer-reviewed journal. It will also be disseminated electronically and in print. Updates of the review will be conducted to provide a summary of the current state of the evidence for the effectiveness of interventions utilising herbal drugs on OME and to guide healthcare practice and policy.

Contributors

The protocol was drafted by all authors. It was revised and the final version approved by all authors.

Funding

No external funding was received. Son MJ was supported by Korea Institute of Oriental Medicine (K13380), Kim YH and Lee HW were supported by same institute (K13101) and Lee MS was supported by same institute (K13400).

Conflicts of interest

None known

References

1. Mandel EM, Casselbrant ML. Recent developments in the treatment of otitis media with effusion. *Drugs* 2006;**66**(12):1565-76

2. Marchica CL, Pitaro J, Daniel SJ. Recurrent tube insertion for chronic otitis media with effusion in children over 6 years. *International journal of pediatric otorhinolaryngology* 2013;**77**(2):252-5

3. Williamson IG, Dunleavy J, Bain J, et al. The natural history of otitis media with effusion--a three-year study of the incidence and prevalence of abnormal tympanograms in four South West Hampshire infant and first schools. *The Journal of laryngology and otology* 1994;**108**(11):930-4

4. Lee HJ, Park SK, Choi KY, et al. Korean clinical practice guidelines: otitis media in children. *Journal of Korean medical science* 2012;**27**(8):835-48

5. Rosenfeld RM, Culpepper L, Doyle KJ, et al. Clinical practice guideline: Otitis media with effusion. *Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery* 2004;**130**(5 Suppl):S95-118

6. Gunasekera H, Knox S, Morris P, et al. The spectrum and management of otitis media in Australian indigenous and nonindigenous children: a national study. *The Pediatric infectious disease journal* 2007;**26**(8):689-92

7. Castagno LA, Lavinsky L. Otitis media in children: seasonal changes and socioeconomic level. *International journal of pediatric otorhinolaryngology* 2002;**62**(2):129-34

8. Eapen RJ, Buss E, Grose JH, et al. The development of frequency weighting for speech in children with a history of otitis media with effusion. *Ear and hearing* 2008;**29**(5):718-

9. Poehling KA, Szilagyi PG, Grijalva CG, et al. Reduction of frequent otitis media and pressure-equalizing tube insertions in children after introduction of pneumococcal conjugate vaccine. *Pediatrics* 2007;**119**(4):707-15
10. Thomas CL, Simpson S, Butler CC, et al. Oral or topical nasal steroids for hearing loss associated with otitis media with effusion in children. The Cochrane database of systematic reviews 2006(3):CD001935
11. Griffin GH, Flynn C, Bailey RE, et al. Antihistamines and/or decongestants for otitis media with effusion (OME) in children. The Cochrane database of systematic reviews 2006(4):CD003423
12. Gunasekera H, Morris PS, McIntyre P, et al. Management of children with otitis media: a summary of evidence from recent systematic reviews. *Journal of paediatrics and child health* 2009;**45**(10):554-62; quiz 62-3
13. Lous J, Burton MJ, Felding JU, et al. Grommets (ventilation tubes) for hearing loss associated with otitis media with effusion in children. The Cochrane database of systematic reviews 2005(1):CD001801
14. Rovers MM, Black N, Browning GG, et al. Grommets in otitis media with effusion: an individual patient data meta-analysis. *Archives of disease in childhood* 2005;**90**(5):480-5
15. Barnes PM, Bloom B, Nahin RL. Complementary and alternative medicine use among adults and children: United States, 2007. *National health statistics reports* 2008(12):1-23
16. Borchers AT, Sakai S, Henderson GL, et al. Shosaiko-to and other Kampo (Japanese herbal) medicines: a review of their immunomodulatory activities. *Journal of ethnopharmacology* 2000;**73**(1-2):1-13

17. Maruyama Y, Hoshida S, Furukawa M, et al. Effects of Japanese herbal medicine, Juzen-taiho-to, in otitis-prone children--a preliminary study. *Acta oto-laryngologica* 2009;**129**(1):14-8

18. Xue CC, Hugel HM, Li CG, et al. Efficacy, chemistry and pharmacology of chinese herbal medicine for allergic rhinitis. *Current medicinal chemistry* 2004;**11**(11):1403-21

19. Sugiura Y, Ohashi Y, Nakai Y. The herbal medicine, sairei-to, prevents endotoxin-induced otitis media with effusion in the guinea pig. *Acta oto-laryngologica Supplementum* 1997;**531**:21-33

20. Sugiura Y, Ohashi Y, Nakai Y. The herbal medicine, sairei-to, enhances the mucociliary activity of the tubotympanum in the healthy guinea pig. *Acta oto-laryngologica Supplementum* 1997;**531**:17-20

21. Levi JR, Brody RM, McKee-Cole K, et al. Complementary and alternative medicine for pediatric otitis media. *International journal of pediatric otorhinolaryngology* 2013;**77**(6):926-31

22. Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. *Cochrane Handbook for Systematic Reviews of Interventions* Version 510 (updated March 2011) The Cochrane Collaboration. Available from www.cochrane-handbook.org, 2011.

23. Sterne JAC, Egger M, Moher D. Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S, eds. *Cochrane Handbook for Systematic Reviews of Interventions* Version 510 (updated March 2011) The Cochrane Collaboration. Available from www.cochrane-handbook.org, 2011.

24. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. *Bmj* 1997;**315**(7109):629-34

- 1
2
3
4 25. Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta-
5
6 analyses. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews
7
8 of Interventions Version 510 (updated March 2011) The Cochrane Collaboration.
9
10 Available from www.cochrane-handbook.org, 2011.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Appendix 1. Search strategies

Table 1 The Cochrane Library (Wiley Online Library)

#1	MeSH descriptor: [Otitis Media with Effusion] explode all trees
#2	glue NEXT ear OR otitis NEXT media NEAR effusion* OR middle NEXT ear NEAR effusion* OR nonsuppurative NEXT otitis OR non NEXT suppurative NEXT otitis
#3	tympanitis OR serous NEXT otitis OR secretory NEXT otitis OR otitis NEXT serosa
#4	mucoid NEAR otitis OR mucous NEAR otitis OR seromuco* NEAR otitis OR sero NEXT muco* NEAR otitis
#5	mucoid NEAR middle NEXT ear OR mucous NEAR middle NEXT ear OR seromuc* NEAR middle NEXT ear
#6	adhesive NEAR otitis OR exudative NEAR otitis
#7	#1 or #2 or #3 or #4 or #5 or #6
#8	MeSH descriptor: [Medicine, Traditional] explode all trees
#9	MeSH descriptor: [Medicine, African Traditional] explode all
#10	MeSH descriptor: [Medicine, Arabic] explode all trees
#11	MeSH descriptor: [Medicine, Ayurvedic] explode all trees
#12	MeSH descriptor: [Medicine, Chinese Traditional] explode all trees
#13	MeSH descriptor: [Medicine, East Asian Traditional] explode all trees
#14	MeSH descriptor: [Medicine, Kampo] explode all trees
#15	MeSH descriptor: [Medicine, Korean Traditional] explode all trees
#16	MeSH descriptor: [Medicine, Mongolian Traditional] explode all trees
#17	MeSH descriptor: [Medicine, Tibetan Traditional] explode all trees
#18	MeSH descriptor: [Plants] explode all trees
#19	MeSH descriptor: [Plants, Medicinal] explode all trees
#20	MeSH descriptor: [Phytotherapy] explode all trees
#21	MeSH descriptor: [Ethnopharmacology] explode all trees
#22	MeSH descriptor: [Ethnobotany] explode all trees
#23	herb* OR plant* OR plant* extract
#24	#8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23
#25	#7 and #24

Table 2 Medline(PubMed)

#1 otitis media with effusion[MeSH Terms]
#2 glue ear
#3 otitis AND media AND effusion*
#4 middle AND ear AND effusion*
#5 nonsuppurative AND otitis
#6 nonsuppurative otitis
#7 tympanitis
#8 serous otitis
#9 secretory otitis
#10 otitis serosa
#11 mucoid AND otitis
#12 mucous AND otitis
#13 seromuco* AND otitis
#14 mucoid AND middle ear
#15 mucous AND middle ear
#16 seromuc* AND middle ear
#17 adhesive AND otitis
#18 exudative AND otitis
#19 or/#1-18
#20 medicine, african traditional[MeSH Terms]
#21 medicine, arabic[MeSH Terms]
#22 medicine, ayurvedic[MeSH Terms]
#23 medicine, traditional[MeSH Terms]
#24 medicine, korean traditional[MeSH Terms]
#25 medicine, kampo[MeSH Terms]
#26 medicine, chinese traditional[MeSH Terms]
#27 Medicine, Tibetan Traditional[MeSH Terms]
#28 Drugs, Chinese Herbal[MeSH Terms]
#29 Medicine, Mongolian Traditional[MeSH Terms]
#30 herb, medicinal[MeSH Terms]

#31	herbal therapy[MeSH Terms]
#32	medicinal plants[MeSH Terms]
#33	plant extracts[MeSH Terms]
#34	ethnobotany[MeSH Terms]
#35	ethnopharmacology[MeSH Terms]
#36	phytotherapy[MeSH Terms]
#37	Plants[MeSH Terms]
#38	herb*[Title/Abstract]
#39	or/#20-38
#40	#19 and #39

Table 3. EMBASE

#1	'secretory otitis media'/exp
#2	'glue'/exp OR glue AND ('ear'/exp OR ear)
#3	'otitis'/exp OR otitis AND media AND ('effusion'/exp OR effusion)
#4	middle AND ('ear'/exp OR ear) AND effusion*
#5	nonsuppurative AND ('otitis'/exp OR otitis)
#6	non AND suppurative AND ('otitis'/exp OR otitis)
#7	'tympanitis'/exp OR tympanitis
#8	serous AND ('otitis'/exp OR otitis)
#9	'serous otitis media'/exp OR 'serous otitis media'
#10	'secretory otitis media'/exp OR 'secretory otitis media'
#11	'otitis'/exp OR otitis AND ('serosa'/exp OR serosa)
#12	mucoid AND ('otitis'/exp OR otitis)
#13	mucous AND ('otitis'/exp OR otitis)
#14	seromuco* AND ('otitis'/exp OR otitis)
#15	sero AND muco* AND ('otitis'/exp OR otitis)
#16	mucoid AND middle AND ('ear'/exp OR ear)
#17	mucous AND middle AND ('ear'/exp OR ear)
#18	seromuc* AND middle AND ('ear'/exp OR ear)
#19	'adhesive'/exp OR adhesive AND ('otitis'/exp OR otitis)

-
- #20 exudative AND ('otitis'/exp OR otitis)
- #21 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR
#11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20
- #22 'traditional medicine'/exp OR 'traditional medicine'
- #23 'african medicine'/exp OR 'african medicine'
- #24 'ayurvedic medicine'/exp OR 'ayurvedic medicine'
- #25 'kampo'/exp OR kampo
- #26 'korean medicine'/exp OR 'korean medicine'
- #27 'latin american medicine'/exp OR 'latin american medicine'
- #28 'mongolian medicine'/exp OR 'mongolian medicine'
- #29 'oriental medicine'/exp OR 'oriental medicine'
- #30 'tibetan traditional medicine'/exp OR 'tibetan traditional medicine'
- #31 'traditional chinese medicine'/exp OR 'traditional chinese medicine'
- #32 'herbal medicine'/exp OR 'herbal medicine'
- #33 'herbal medicinal product'/exp OR 'herbal medicinal product'
- #34 'herbaceous agent'/exp OR 'herbaceous agent'
- #35 'medicinal plant'/exp OR 'medicinal plant'
- #36 'plant'/exp OR plant
- #37 'plant extract'/exp OR 'plant extract'
- #38 'phytotherapy'/exp OR phytotherapy
- #39 'ethnopharmacology'/exp OR ethnopharmacology
- #40 'ethnobotany'/exp OR ethnobotany
- #41 #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30
OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40
- #42 #21 AND #41
-



Oral administration of herbal medicines for the treatment of otitis media with effusion: Protocol for a systematic review

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-004095.R1
Article Type:	Protocol
Date Submitted by the Author:	14-Jan-2014
Complete List of Authors:	Kim, Yun Hee; Korea Institute of Oriental Medicine, Son, Mi-Ju; Korea Institute of Oriental Medicine, Literature & Informatics Research Division Kim, Young-Eun; Korea Institute of Oriental Medicine, Lee, Hye Won; Korea Institute of Oriental Medicine, Lee, Myeong Soo; Korea Institute of Oriental Medicine,
Primary Subject Heading:	Cardiovascular medicine
Secondary Subject Heading:	Complementary medicine, Ear, nose and throat/otolaryngology
Keywords:	COMPLEMENTARY MEDICINE, OTOLARYNGOLOGY, Herbal medicine < THERAPEUTICS

SCHOLARONE™
Manuscripts

Oral administration of herbal medicines for the treatment of otitis media with effusion: Protocol for a systematic review

Yun Hee Kim,^{1,†} Mi Ju Son,^{2,†} Young-Eun Kim,² Hye Won Lee,¹ Myeong Soo Lee^{3,*}

¹*Herbal Medicine Research Division,* ²*Medical Culture & Informatics Research Division,*

³*Medical Research Division, Korea Institute of Oriental Medicine, Daejeon, South Korea*

[†] Equally contributed

Running title: Oral administration of herbal medicines for otitis media with effusion

***Correspondence to:**

Myeong Soo Lee, PhD
Medical Research Division,
Korea Institute of Oriental Medicine,
Daejeon, 305-811, South Korea
Tel: 82-(0)42-868-9266
Fax: 82-(0)42-868-9622
E-mail: drmslee@gmail.com

Kim YH: ddyunee@kiom.re.kr
Son MJ: mj714@kiom.re.kr
Kim Y-E: jade2010@kiom.re.kr
Lee HY: hwlee@kiom.re.kr
Lee MS: drmslee@gmail.com

License statement

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non-exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd and its Licensees to permit this article (if accepted) to be published in BMJ Open and any other BMJ PGL products to exploit all subsidiary rights, as set out in our licence (<http://group.bmj.com/products/journals/instructions-for-authors/licence-forms>).

Abstract

Introduction: The purpose of this systematic review is to investigate the efficacy of the oral administration of herbal medicines for otitis media with effusion (OME) through analysing trial data.

Methods and analysis: Electronic searches of the following eleven databases will be performed: MEDLINE, CINAHL, EMBASE, AMED, the Cochrane CENTRAL, three Chinese databases (CNKI, Wangfang Data and VIP Information) and five Korean databases (KoreaMed, Research Information Service System, Korea Studies Information System, Oriental Medicine Advanced Searching Integrated System (OASIS) and DBpia). The selection of the studies, data abstraction, and validations will be performed independently by two researchers.

Dissemination: The systematic review will be published in a peer-reviewed journal. The review will also be disseminated electronically and in print. The review will be updated to inform and guide healthcare practice and policy.

Trial registration number: PROSPERO 2013: CRD42013005430.

Keywords: Herbal medicine, complementary and alternative medicine, otitis media, effusion, systematic review, protocol

Article focus

- The aim of the proposed systematic review is to analyse trial data concerning the efficacy of the oral administration of herbal medicines for otitis media with effusion.

Key messages

- This systematic review will be performed using a comprehensive search strategy and will establish the current status of the evidence using unbiased methods.

Strengths and limitations of this study

- The strength of this systematic review is its extensive, unbiased search of various databases without a language restriction.
- The trial screening and data extraction will be conducted independently by two of the authors.

Introduction

Description of the condition

Otitis media with effusion (OME) is characterised by the presence of middle-ear effusion without the signs and symptoms of an acute ear infection and a disease course of months until recovery.¹⁻⁴ Otitis media affects nearly every child at least once, and approximately 90% of children experience an episode of OME before reaching school age.^{5,6} The aetiology of OME is uncertain, but poor clearance due to poor Eustachian tube function, local inflammatory reactions, low-grade infection, allergic reactions and adenoidal infection or hypertrophy have been implicated.⁷ Many episodes resolve spontaneously within three months, but approximately 35% to 50% of OME patients experience chronic or recurrent states of this disease. Persistent, symptomatic and untreated OME may lead to major functional limitations such as permanent hearing loss, which may delay language, speech and cognitive development.⁸⁻¹⁰ The high prevalence and potential complications of OME cause high socioeconomic consequences, the loss of the caregivers' income and working time and the children's time in addition to the medical costs. The combined direct and indirect annual cost of OME was \$4 billion in the United States.^{4,5}

Description of the intervention

Antibiotics and steroids have been suggested to provide only a marginal benefit, and antihistamines are not recommended in systematic reviews. Thus, based on the current evidence regarding the efficacy of treatments for OME, the recommendation is to not administer medications but instead follow an observational policy for at least three months from its onset.¹¹⁻¹³ The decision to provide surgical treatment is to be considered after 3 months of observation with evaluation of hearing. A review of randomised controlled trials

revealed that the insertion of ventilation tubes reduced the proportion of time spent with effusion compared with watchful waiting. However, surgical treatment may lead to adverse effects, such as tympanosclerosis and tympanic membrane abnormalities.^{14 15}

Currently, many patients who are seeking ways to relieve the symptoms associated with chronic OME or to avoid the side effects of conventional treatment have chosen complementary and alternative medicine (CAM). Herbal medicine, a part of CAM, is the medical utilisation of medicinal plants, minerals and animal parts to prevent or treat clinical conditions.¹⁶ According to the survey data, herbal medicine was commonly used to treat respiratory problems, digestive problems, allergies and insomnia. A US survey indicated that 16.4% of patients visiting an internal medicine clinic currently used herbal medicines.^{17 18}

How the intervention might work

Many types of herbal medicines are known to have immunomodulatory properties and to show anti-inflammatory efficacy in clinical research.¹⁹⁻²¹ In experimental research, herbal medicines reduced swelling and prevented endotoxin-induced otitis media through stimulating the mucociliary system for pathogen clearance. Additionally, many types of herbal medicines had anti-inflammatory and anti-bacterial effects in experiments using an otitis media animal model.²²⁻²⁶ However, the mechanisms underlying the observed immunomodulatory properties of herbal medicines are currently unclear.

Why it is important to perform this review

Notwithstanding the increased use of herbal medicines in the treatment of otitis media, no systematic reviews assessing the intervention of herbal drugs treatment for OME have been

conducted to date.^{16 27} Understanding the efficacy and safety of herbal medicines will allow the appropriate recommendation of an herbal drug treatment for patients.

Objectives

Thus, we propose to undertake a systematic review to assess the safety and efficacy of herbal drugs for the treatment of OME.

Methods

Criteria for considering studies for this review

Types of studies

Randomised controlled trials (RCTs) and quasi-RCTs (the group allocation was not purely random but rather determined by a factor such as a birth date, a hospital record number or an alternation) will be included. Cluster RCTs, case studies, case series, qualitative studies and uncontrolled trials will be excluded. Trials that do not provide detailed results will also be excluded. Dissertations and abstracts will be included if these contain sufficient details for critical evaluation. No language restriction will be imposed. If we encounter languages other than English, Korean, and Chinese, we will either contact the original authors or obtain a translation of the manuscript from professional service.

Types of participants

The studies that evaluated patients who had a diagnosis of OME will be included. The diagnostic criteria for OME should be based on the criteria of the American Academy of Pediatrics (AAP) and the American Academy of Otolaryngology and Head and Neck Surgery (AAOHN).⁵ We will exclude studies of patients with ventilation tubes present, patients with an anatomical deformity or patients with other chronic immune-compromised states.

Types of interventions

We will include those trials using the oral administration of herbal medicine alone or as a combined therapy of the oral administration of herbal medicine with a conventional therapy versus the same conventional therapy. Herbal medicine is defined as a single herb, an individually prescribed herbal formula or herbal products extracted from natural herbs. There

is no limitation on the number of herbs used, the dosage, the forms of medication or the duration of the treatment. We will include only the oral administration of the medication.

Types of outcome measures

The following outcome measures will be assessed based on analyses of the data obtained in the included trials:

Primary Outcome

Complete resolution of OME (however measured) at two or three months post-randomisation (resolution in the affected ear in participants with unilateral OME at randomisation and resolution in both ears of those with bilateral OME)

Secondary Outcomes

1. Partial or complete resolution of OME at all possible time points
2. Duration of hearing loss as defined by pure-tone audiometric loss of more than 20 dB
3. Language and speech development
4. Cognitive development
5. Insertion of ventilation tubes
6. Tympanic membrane sequelae
7. Reduction of complication of OME
8. Quality of life
8. Adverse effects likely to be related to treatment

Search methods for identifying the studies

Electronic searches

The electronic searches will be performed using MEDLINE, the Cumulative Index to Nursing and Allied Health Literature (CINAHL), EMBASE, the Allied and Complementary Medicine Database (AMED) and the Cochrane Central Register of Controlled Trials (CENTRAL). We will also search three Chinese databases (China Network Knowledge Infrastructure (CNKI), Wangfang Data and VIP Information) and five Korean databases (KoreaMed, the Research Information Service System (RISS), Oriental Medicine Advanced Searching Integrated System (OASIS), DBPIA, and the Korean Studies Information Service System (KISS)).

Searching other resources

Ongoing studies will be sought in the meta-Register of Controlled Trials (mRCT) (www.controlled-trials.com/mrct), Clinical trials.gov (www.clinicaltrials.gov) and the WHO International Clinical Trials Registry platform (ICTRP) (<http://apps.who.int/trialsearch/>), all of which list ongoing trials. The bibliographic references of all of the included trials will be reviewed to identify other relevant studies. We will also contact the authors of the trial studies and experts in the field.

Search strategy

The strategies for searching The Cochrane Library, MEDLINE, and EMBASE databases are presented in Appendix 1. These strategies will be modified for use with other databases.

Data collection and analysis

Selection of studies

Two of the review's authors (Son MJ and Kim YH) will independently screen the titles and abstracts of the searched studies, perform the study selection and record their decisions on a standard eligibility form. The arbitrator (Lee MS) will decide upon the study selection when a consensus cannot be reached. The details of selection process will be shown in PRISMA flow diagram (Figure 1).

Data extraction and management

Two of the authors (Son MJ and Kim YH) will independently extract the data using a standard data extraction form and resolve disagreements through discussion before analysis. When the reported data are insufficient or ambiguous, two of the authors (Kim YE and Lee HW) will contact the corresponding authors of the clinical trials by e-mail or telephone to request additional information or clarification.

Assessment of risk of bias in the included studies

We will independently assess the risk of bias in the eligible studies according to the criteria described in the Cochrane Handbook version 5.1.0, which include random sequence generation, allocation concealment, blinding of participants and personnel, blinding of the outcome assessment, incomplete outcome data, selective reporting, and other sources of bias.²⁸ The quality of the study will be classified as low, unclear or high risk of bias. If necessary, we will contact the authors of eligible trials for clarification. Any differences in opinion will be resolved by discussion or arbitration involving a third author.

Measures of the treatment effect

For continuous data, we will use the mean difference (MD) to measure the treatment effect at a 95% confidence interval (CI). We will convert other forms of data into MDs. In the case of outcome variables with different scales, we will use the standard mean difference (SMD) with a 95% CI. For dichotomous data, we will present the treatment effects as a relative risk (RR) or risk difference (RD) with 95% CIs. Based on these results, we will calculate the associated numbers needed to treat (NNT).

Unit of analysis issues

Data from parallel-group studies will be included for meta-analysis. If there are cross-over trials, the first phase of the data will be adopted for analysis.

Managing missing data

We will request missing data from the original authors, whenever possible. If it is not possible to do this, we will only analyse the available data.

Assessment of heterogeneity

If a meta-analysis is possible, we will use the I^2 statistic to quantify the inconsistencies among the included studies. An I^2 value of >50% will be considered indicative of substantial heterogeneity.³¹ If heterogeneity is observed, we will conduct a subgroup analysis to explore its possible causes.³¹

Assessment of reporting biases

We will prepare funnel plots to assess the reporting biases if sufficient studies are available (at least 10 trials).²⁹ However, funnel plot asymmetry is not the same as publication bias;

therefore, we will attempt to distinguish the different possible reasons for the asymmetry, such as small-study effects, poor methodological quality and the true heterogeneity of the included studies.^{29 30}

Data synthesis

Data synthesis for comparable trials with comparable outcomes will be performed using Review Manager (RevMan), Version 5.2.6.

Subgroup analysis and investigation of heterogeneity

If the data are available, a predefined subgroup analysis will be conducted to assess the heterogeneity of different studies, including the following:

1. Laterality of OME: bilateral OME versus unilateral OME
2. Duration of OME: any duration of OME versus persistent OME (lasting for more than two or three months)
3. Duration of treatment
4. Type of herbal medicine
5. Type of control
6. Type of age group (participants aged over 18 years versus children aged two years or more versus children younger than two years)

Sensitivity analysis

Sensitivity analysis will principally be performed as follows:

1. Sample size (e.g., more or less than 40 participants in each group)
2. Low risk of bias (e.g., allocation concealment or the blinding of participants/assessors)

For peer review only

Discussion

Because no primary data collection will be undertaken, no additional formal ethical assessment or informed consent is required. The systematic review will be published in a peer-reviewed journal. It will also be disseminated electronically and in print. The review will be updated, and a GRADE evaluation of the quality of evidence will be conducted to provide summaries of the future state of the evidence for the efficacy of interventions utilising herbal drugs on OME. The review may guide healthcare practices and policies regarding the oral administration of herbal medicines to treat OME.

Contributors

The protocol was drafted by all authors. It was revised and the final version approved by all authors.

Funding

No external funding was received.

Conflicts of interest

None known

References

1. Mandel EM, Casselbrant ML. Recent developments in the treatment of otitis media with effusion. *Drugs* 2006;**66**(12):1565-76
2. Marchica CL, Pitaro J, Daniel SJ. Recurrent tube insertion for chronic otitis media with effusion in children over 6 years. *International journal of pediatric otorhinolaryngology* 2013;**77**(2):252-5
3. Williamson IG, Dunleavy J, Bain J, et al. The natural history of otitis media with effusion--a three-year study of the incidence and prevalence of abnormal tympanograms in four South West Hampshire infant and first schools. *The Journal of laryngology and otology* 1994;**108**(11):930-4
4. Lee HJ, Park SK, Choi KY, et al. Korean clinical practice guidelines: otitis media in children. *Journal of Korean medical science* 2012;**27**(8):835-48
5. Rosenfeld RM, Culpepper L, Doyle KJ, et al. Clinical practice guideline: Otitis media with effusion. *Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery* 2004;**130**(5 Suppl):S95-118
6. Gunasekera H, Knox S, Morris P, et al. The spectrum and management of otitis media in Australian indigenous and nonindigenous children: a national study. *The Pediatric infectious disease journal* 2007;**26**(8):689-92
7. Paul W. Flint, Bruce H. Haughey, Valerie J. Lund, et al. *Cummings Otolaryngology Head & Neck Surgery* Philadelphia: MOSBY ELSEVIER, 2010.
8. Castagno LA, Lavinsky L. Otitis media in children: seasonal changes and socioeconomic level. *International journal of pediatric otorhinolaryngology* 2002;**62**(2):129-34
9. Eapen RJ, Buss E, Grose JH, et al. The development of frequency weighting for speech in children with a history of otitis media with effusion. *Ear and hearing* 2008;**29**(5):718-24

10. Poehling KA, Szilagyi PG, Grijalva CG, et al. Reduction of frequent otitis media and pressure-equalizing tube insertions in children after introduction of pneumococcal conjugate vaccine. *Pediatrics* 2007;**119**(4):707-15
11. Thomas CL, Simpson S, Butler CC, et al. Oral or topical nasal steroids for hearing loss associated with otitis media with effusion in children. The Cochrane database of systematic reviews 2006(3):CD001935
12. Griffin GH, Flynn C, Bailey RE, et al. Antihistamines and/or decongestants for otitis media with effusion (OME) in children. The Cochrane database of systematic reviews 2006(4):CD003423
13. Gunasekera H, Morris PS, McIntyre P, et al. Management of children with otitis media: a summary of evidence from recent systematic reviews. *Journal of paediatrics and child health* 2009;**45**(10):554-62; quiz 62-3
14. Lous J, Burton MJ, Felding JU, et al. Grommets (ventilation tubes) for hearing loss associated with otitis media with effusion in children. The Cochrane database of systematic reviews 2005(1):CD001801
15. Rovers MM, Black N, Browning G, et al. Grommets in otitis media with effusion: an individual patient data meta-analysis. *Archives of disease in childhood* 2005;**90**(5):480-5
16. Barnes PM, Bloom B, Nahin RL. Complementary and alternative medicine use among adults and children: United States, 2007. *National health statistics reports* 2008(12):1-23
17. Ernst E. The efficacy of herbal medicine--an overview. *Fundamental & clinical pharmacology* 2005;**19**(4):405-9
18. Rhee SM, Garg VK, Hershey CO. Use of complementary and alternative medicines by ambulatory patients. *Archives of internal medicine* 2004;**164**(9):1004-9

19. Wen MC, Wei CH, Hu ZQ, et al. Efficacy and tolerability of anti-asthma herbal medicine intervention in adult patients with moderate-severe allergic asthma. *The Journal of allergy and clinical immunology* 2005;**116**(3):517-24
20. Cohen HA, Varsano I, Kahan E, et al. Effectiveness of an herbal preparation containing echinacea, propolis, and vitamin C in preventing respiratory tract infections in children: a randomized, double-blind, placebo-controlled, multicenter study. *Archives of pediatrics & adolescent medicine* 2004;**158**(3):217-21
21. Amirghofran Z, Azadbakht M, Karimi MH. Evaluation of the immunomodulatory effects of five herbal plants. *Journal of ethnopharmacology* 2000;**72**(1-2):167-72
22. Borchers AT, Sakai S, Henderson GL, et al. Shosaiko-to and other Kampo (Japanese herbal) medicines: a review of their immunomodulatory activities. *Journal of ethnopharmacology* 2000;**73**(1-2):1-13
23. Maruyama Y, Hoshida S, Furukawa M, et al. Effects of Japanese herbal medicine, Juzen-taiho-to, in otitis-prone children--a preliminary study. *Acta oto-laryngologica* 2009;**129**(1):14-8
24. Xue CC, Hugel HM, Li CG, Story DF. Efficacy, chemistry and pharmacology of chinese herbal medicine for allergic rhinitis. *Current medicinal chemistry* 2004;**11**(11):1403-21
25. Sugiura Y, Ohashi Y, Nakai Y. The herbal medicine, sairei-to, prevents endotoxin-induced otitis media with effusion in the guinea pig. *Acta oto-laryngologica. Supplementum* 1997;**531**:21-33
26. Sugiura Y, Ohashi Y, Nakai Y. The herbal medicine, sairei-to, enhances the mucociliary activity of the tubotympanum in the healthy guinea pig. *Acta oto-laryngologica. Supplementum* 1997;**531**:17-20

27. Levi JR, Brody RM, McKee-Cole K, et al. Complementary and alternative medicine for pediatric otitis media. *International journal of pediatric otorhinolaryngology* 2013;**77**(6):926-31

28. Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. *Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)*. : The Cochrane Collaboration. Available from www.cochrane-handbook.org, 2011.

29. Sterne JAC, Egger M, Moher D. Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S, eds. *Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)*. : The Cochrane Collaboration. Available from www.cochrane-handbook.org, 2011.

30. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. *Bmj* 1997;**315**(7109):629-34

31. Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S, eds. *Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)*. : The Cochrane Collaboration. Available from www.cochrane-handbook.org, 2011.

Figure legends

Figure 1. Study selection flow diagram

For peer review only

Appendix 1. Search strategies

Table 1 The Cochrane Library (Wiley Online Library)

#1	MeSH descriptor: [Otitis Media with Effusion] explode all trees
#2	glue NEXT ear OR otitis NEXT media NEAR effusion* OR middle NEXT ear NEAR effusion* OR nonsuppurative NEXT otitis OR non NEXT suppurative NEXT otitis
#3	tympanitis OR serous NEXT otitis OR secretory NEXT otitis OR otitis NEXT serosa
#4	mucoid NEAR otitis OR mucous NEAR otitis OR seromuco* NEAR otitis OR sero NEXT muco* NEAR otitis
#5	mucoid NEAR middle NEXT ear OR mucous NEAR middle NEXT ear OR seromuc* NEAR middle NEXT ear
#6	adhesive NEAR otitis OR exudative NEAR otitis
#7	#1 or #2 or #3 or #4 or #5 or #6
#8	MeSH descriptor: [Medicine, Traditional] explode all trees
#9	MeSH descriptor: [Medicine, African Traditional] explode all
#10	MeSH descriptor: [Medicine, Arabic] explode all trees
#11	MeSH descriptor: [Medicine, Ayurvedic] explode all trees
#12	MeSH descriptor: [Medicine, Chinese Traditional] explode all trees
#13	MeSH descriptor: [Medicine, East Asian Traditional] explode all trees
#14	MeSH descriptor: [Medicine, Kampo] explode all trees
#15	MeSH descriptor: [Medicine, Korean Traditional] explode all trees
#16	MeSH descriptor: [Medicine, Mongolian Traditional] explode all trees
#17	MeSH descriptor: [Medicine, Tibetan Traditional] explode all trees
#18	MeSH descriptor: [Plants] explode all trees
#19	MeSH descriptor: [Plants, Medicinal] explode all trees
#20	MeSH descriptor: [Phytotherapy] explode all trees
#21	MeSH descriptor: [Ethnopharmacology] explode all trees
#22	MeSH descriptor: [Ethnobotany] explode all trees
#23	herb* OR plant* OR plant* extract
#24	#8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23
#25	#7 and #24

Table 2 Medline(PubMed)

#1 otitis media with effusion[MeSH Terms]
#2 glue ear
#3 otitis AND media AND effusion*
#4 middle AND ear AND effusion*
#5 nonsuppurative AND otitis
#6 nonsuppurative otitis
#7 tympanitis
#8 serous otitis
#9 secretory otitis
#10 otitis serosa
#11 mucoid AND otitis
#12 mucous AND otitis
#13 seromuco* AND otitis
#14 mucoid AND middle ear
#15 mucous AND middle ear
#16 seromuc* AND middle ear
#17 adhesive AND otitis
#18 exudative AND otitis
#19 or/#1-18
#20 medicine, african traditional[MeSH Terms]
#21 medicine, arabic[MeSH Terms]
#22 medicine, ayurvedic[MeSH Terms]
#23 medicine, traditional[MeSH Terms]
#24 medicine, korean traditional[MeSH Terms]
#25 medicine, kampo[MeSH Terms]
#26 medicine, chinese traditional[MeSH Terms]
#27 Medicine, Tibetan Traditional[MeSH Terms]
#28 Drugs, Chinese Herbal[MeSH Terms]
#29 Medicine, Mongolian Traditional[MeSH Terms]
#30 herb, medicinal[MeSH Terms]

#31	herbal therapy[MeSH Terms]
#32	medicinal plants[MeSH Terms]
#33	plant extracts[MeSH Terms]
#34	ethnobotany[MeSH Terms]
#35	ethnopharmacology[MeSH Terms]
#36	phytotherapy[MeSH Terms]
#37	Plants[MeSH Terms]
#38	herb*[Title/Abstract]
#39	or/#20-38
#40	#19 and #39

Table 3. EMBASE

#1	'secretory otitis media'/exp
#2	'glue'/exp OR glue AND ('ear'/exp OR ear)
#3	'otitis'/exp OR otitis AND media AND ('effusion'/exp OR effusion)
#4	middle AND ('ear'/exp OR ear) AND effusion*
#5	nonsuppurative AND ('otitis'/exp OR otitis)
#6	non AND suppurative AND ('otitis'/exp OR otitis)
#7	'tympanitis'/exp OR tympanitis
#8	serous AND ('otitis'/exp OR otitis)
#9	'serous otitis media'/exp OR 'serous otitis media'
#10	'secretory otitis media'/exp OR 'secretory otitis media'
#11	'otitis'/exp OR otitis AND ('serosa'/exp OR serosa)
#12	mucoid AND ('otitis'/exp OR otitis)
#13	mucous AND ('otitis'/exp OR otitis)
#14	seromuco* AND ('otitis'/exp OR otitis)
#15	sero AND muco* AND ('otitis'/exp OR otitis)
#16	mucoid AND middle AND ('ear'/exp OR ear)
#17	mucous AND middle AND ('ear'/exp OR ear)
#18	seromuc* AND middle AND ('ear'/exp OR ear)
#19	'adhesive'/exp OR adhesive AND ('otitis'/exp OR otitis)

-
- #20 exudative AND ('otitis'/exp OR otitis)
- #21 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR
#11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20
- #22 'traditional medicine'/exp OR 'traditional medicine'
- #23 'african medicine'/exp OR 'african medicine'
- #24 'ayurvedic medicine'/exp OR 'ayurvedic medicine'
- #25 'kampo'/exp OR kampo
- #26 'korean medicine'/exp OR 'korean medicine'
- #27 'latin american medicine'/exp OR 'latin american medicine'
- #28 'mongolian medicine'/exp OR 'mongolian medicine'
- #29 'oriental medicine'/exp OR 'oriental medicine'
- #30 'tibetan traditional medicine'/exp OR 'tibetan traditional medicine'
- #31 'traditional chinese medicine'/exp OR 'traditional chinese medicine'
- #32 'herbal medicine'/exp OR 'herbal medicine'
- #33 'herbal medicinal product'/exp OR 'herbal medicinal product'
- #34 'herbaceous agent'/exp OR 'herbaceous agent'
- #35 'medicinal plant'/exp OR 'medicinal plant'
- #36 'plant'/exp OR plant
- #37 'plant extract'/exp OR 'plant extract'
- #38 'phytotherapy'/exp OR phytotherapy
- #39 'ethnopharmacology'/exp OR ethnopharmacology
- #40 'ethnobotany'/exp OR ethnobotany
- #41 #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30
OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40
- #42 #21 AND #41
-

Herbal Oral administration of herbal medicines for the treatment of otitis media with effusion: Protocol for a systematic review

Yun Hee Kim,^{1,†} Mi Ju Son,^{2,†} Young-Eun Kim,² Hye Won Lee,¹ Myeong Soo Lee^{3,*}

¹Herbal Medicine Research Division, ²Literature²Medical Culture & Informatics Research Division, ³Medical Research Division, Korea Institute of Oriental Medicine, Daejeon, South Korea

[†] Equally contributed

Running title: Herbal Oral administration of herbal medicines for otitis media with effusion

Keywords: Herbal medicine, complementary and alternative medicine, otitis media, effusion, systematic review, protocol

***Correspondence to:**
Myeong Soo Lee, PhD
Medical Research Division,
Korea Institute of Oriental Medicine,
Daejeon, 305-811, South Korea
Tel: 82-(0)42-868-9266
Fax: 82-(0)42-868-9622

Style Definition: Comment Text: Font: Calibri, 10 pt

Formatted: English (U.K.)

Formatted: Font color: Auto

Formatted: Font color: Auto

Formatted: Default Paragraph Font, Font color: Auto, English (U.S.)

Formatted: Justified, Line spacing: Double

Formatted: Line spacing: Double

E-mail: drmslee@gmail.com

Kim YH: ddyunee@kiom.re.kr
Son MJ: mj714@kiom.re.kr
Kim Y-E: jade2010@kiom.re.kr
Lee HY: hwlee@kiom.re.kr
Lee MS: drmslee@gmail.com

License statement

The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non-exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd and its Licensees to permit this article (if accepted) to be published in BMJ Open and any other BMJPGl products to exploit all subsidiary rights, as set out in our licence (<http://group.bmj.com/products/journals/instructions-for-authors/licence-forms>).

For peer review only

Article focus

- The aim of the proposed systematic review is to analyse trial data concerning the effectiveness/efficacy of the oral administration of herbal medicines for otitis media with effusion.

Key messages

- This systematic review will be performed using a comprehensive search strategy and will establish the current status of the evidence using unbiased methods.

Strengths and limitations of this study

- The strength of this systematic review is its extensive, unbiased search of various databases without a language restriction.
- The trial screening and data extraction will be conducted independently by two of the authors.

Abstract

Introduction: The purpose of this systematic review is to investigate the effectiveness/efficacy of the oral administration of herbal medicines for otitis media with effusion (OME) through analysing trial data.

Formatted: Default Paragraph Font, Font color: Auto, English (U.S.)

Methods and analysis: Electronic searches of the following eleven databases will be performed: MEDLINE, ~~the Cumulative Index to Nursing and Allied Health Literature (CINAHL)~~, EMBASE, ~~the Allied and Complementary Medicine Database (AMED)~~, the Cochrane Central Register of Controlled Trials (CENTRAL), ~~the China Network Knowledge Infrastructure~~, three Chinese databases (CNKI, Wangfang Data and VIP Information) and five Korean databases ~~{(KoreaMed, Research Information Service System, Korea Studies Information System, DBPIA, Korea Med, Research Information Service System (RISS) and the Korean Studies Information Service System (KISS)) and DBpia}~~. The selection of the studies, data abstraction, and validations will be performed independently by two researchers.

Dissemination: The systematic review will be published in a peer-reviewed journal. The review will also be disseminated electronically and in print. ~~Updates of the~~The review will be ~~conducted~~updated to inform and guide healthcare practice and policy.

Trial registration number: PROSPERO 2013: CRD42013005430.

Formatted: Indent: Left: 0"

Keywords: Herbal medicine, complementary and alternative medicine, otitis media, effusion, systematic review, protocol

Formatted: Default Paragraph Font, Font color: Auto, English (U.S.)

Formatted: Justified, Line spacing: Double

Formatted: Line spacing: Double

Introduction

Description of the condition

Otitis media with effusion (OME) is characterised ~~as by~~ the presence of middle-ear effusion without the signs and symptoms of an acute ear infection and a disease course of months until recovery. ~~[1-4]. OM.~~ ¹⁻⁴ Otitis media affects nearly every child at least once, and approximately 90% of children experience an episode of OME before reaching school age. ^{5,6}

~~The aetiology of OME is uncertain, but poor clearance due to incomplete poor Eustachian tube functioning function, local inflammatory reactions, low-grade infection, allergic reactions and adenoidal infection or inflammation following acute otitis media (AOM) [5-6].~~

~~Approximately hypertrophy have been implicated.~~ ⁷ Many episodes resolve spontaneously within three months, but approximately 35% to 50% of OME patients ~~have experience~~ chronic or recurrent states. ~~When inadequately treated, OME can cause of this disease.~~

~~Persistent, symptomatic and untreated OME may lead to~~ major functional limitations such as permanent hearing loss, which may delay language, speech and cognitive development. ~~[7-9].~~

⁸⁻¹⁰ ~~The high prevalence and potential complications of OME cause high socioeconomic consequences, the loss of the caregivers' income and working time and the children's time in addition to the medical costs. The combined direct and indirect annual cost of OME was \$4 billion in the United States.~~ ^{4,5}

Description of the intervention

~~OME has high socioeconomic consequences, and the annual cost of OME was \$4 billion.~~ ⁴

~~Patients with OME are treated with antibiotics, antihistamines, steroids and the insertion of ventilation tubes. However, antibiotics~~ Antibiotics and steroids have been suggested to

provide only a marginal benefit, and antihistamines are not recommended in systematic reviews.^[10-12] Thus, based on the current evidence regarding the efficacy of treatments for OME, the recommendation is to not administer medications but instead follow an observational policy for at least three months from its onset.¹¹⁻¹³ The decision to provide surgical treatment is to be considered after 3 months of observation with evaluation of hearing. A review of randomised controlled trials revealed that the insertion of ventilation tubes reduced the proportion of time spent with effusion compared with watchful waiting. However, ~~ventilation tubes~~surgical treatment may lead to adverse effects, such as tympanosclerosis and tympanic membrane abnormalities.^{[13-14], 14 15}

How the intervention might work

Currently, many patients who are seeking ways to relieve the symptoms associated with chronic OME or to avoid the side effects of conventional treatment have chosen complementary and alternative medicine (CAM).^[15] Herbal medicine, a part of CAM, is the ~~use~~medical utilisation of medicinal plants, minerals and animal parts ~~for preventing to prevent~~ or ~~treat~~treat clinical conditions.¹⁶ According to the survey data, herbal medicine was commonly used to treat respiratory problems, digestive problems, allergies and insomnia. A US survey indicated that 16.4% of patients visiting an internal medicine clinic currently used herbal medicines.^{17 18}

How the intervention might work

Many types of herbal medicines are known to have ~~an~~immunomodulatory properties and to show anti-inflammatory effects and have been to reduce efficacy in clinical research.¹⁹⁻²¹ In

Formatted: Font: Bold, Italic

Formatted: Indent: First line: 0"

Formatted: Font color: Black

Formatted: Font color: Black

Formatted: Font color: Black

Formatted: Font: Bold, Italic

Formatted: Indent: First line: 0"

Formatted: Font color: Black

experimental research, herbal medicines reduced swelling and prevented endotoxin-induced OME in experimental investigations [16-20]. otitis media through stimulating the mucociliary system for pathogen clearance. Additionally, many types of herbal medicines had anti-inflammatory and anti-bacterial effects in experiments using an otitis media animal model. ²²⁻²⁶ However, the mechanisms underlying the observed immunomodulatory properties of herbal medicines are currently unclear.

Formatted: Font color: Black

Formatted: Font color: Black

Formatted: Font color: Auto

Why it is important to perform this review

Herbal medicine has been approved by Notwithstanding the World Health Organization as a therapy for increased use of herbal medicines in the treatment of OME [15-21]. However, otitis media, no systematic reviews assessing the intervention of herbal drugs treatment infor OME have been conducted to date. ¹⁶⁻²⁷ Understanding the effectiveness efficacy and safety of herbal medicines will allow the appropriate recommendation of an herbal drug treatment for patients.

Formatted: Font color: Black

Formatted: Font color: Auto

Objectives

Thus, we will propose to undertake a systematic review to assess the safety and efficacy of herbal drugs for the treatment of OME.

Methods

Criteria for considering studies for this review

Types of studies

~~The review will include randomised~~ Randomised controlled trials, ~~including cluster randomised trials. Quasi-randomised trials, in which~~ (RCTs) and quasi-RCTs (the group allocation was not purely random but rather determined by a factor such as a birth date, a hospital record number or ~~alternation, will be included. Any trials without parallel comparisons or control groups will be excluded~~ an alternation) will be included. Cluster RCTs, case studies, case series, qualitative studies and uncontrolled trials will be excluded. Trials that do not provide detailed results will also be excluded. Dissertations and abstracts will be included if these contain sufficient details for critical evaluation. No language restriction will be imposed. If we encounter languages other than English, Korean, and Chinese, we will either contact the original authors or obtain a translation of the manuscript from professional service.

Types of participants

The ~~review will include~~ studies ~~evaluating~~ that evaluated patients who had a diagnosis of OME; ~~will be included.~~ The diagnostic criteria for OME should be based on the criteria of ~~the WHO,~~ the American Academy of Pediatrics (AAP) and the American Academy of Otolaryngology and Head and Neck Surgery (AAOHN), ~~but if necessary, trials for which the definition of OME used by the authors is in question will also be included.~~⁵ We will exclude studies of patients with ventilation tubes present, patients with an anatomical deformity or patients with other chronic immune-compromised states.

Types of interventions

~~The review~~We will include those trials using the oral administration of herbal medicine alone or as a combined therapy of the oral administration of herbal medicine with a conventional therapy versus the same conventional therapy. Herbal medicine is defined as a single herb, an individually prescribed herbal formula or herbal products extracted from natural herbs. There is no limitation on the number of herbs used, the dosage, the forms of medication or the duration of the treatment. We will include only the oral administration of the medication.

Types of outcome measures

The following outcome measures will be assessed based on analyses of the data obtained in the included trials:

Primary Outcome

~~Resolution of symptoms or signs (however measured)~~

Complete resolution of OME (however measured) at two or three months post-randomisation (resolution in the affected ear in participants with unilateral OME at randomisation and resolution in both ears of those with bilateral OME)

Secondary Outcomes

1. Partial or complete resolution of OME at all possible time points

2. Duration of effusion

2. Hearing levelhearing loss as defined by pure-tone audiometric loss of more than 20 dB

3. Language and speech development

4. Cognitive development

5. Insertion of ventilation tubes

6. ~~New AOM~~ Tympanic membrane sequelae

~~7. Tympanic membrane sequelae~~

7. Reduction of complication of OME

8. Quality of life

~~98.~~ Adverse effects likely to be related to treatment

Search methods for identifying the studies

Electronic searches

The electronic searches will be performed using MEDLINE, the Cumulative Index to Nursing and Allied Health Literature (CINAHL), EMBASE, the Allied and Complementary Medicine Database (AMED) and the Cochrane Central Register of Controlled Trials (CENTRAL). We will also search ~~one~~ three Chinese ~~database~~ databases (China Network Knowledge Infrastructure (CNKI)), Wangfang Data and VIP Information) and five Korean databases ~~(KoreaMed, the Research Information Service System (RISS), Oriental Medicine Advanced Searching Integrated System (OASIS), DBPIA, Korea Med, the Research Information Service System (RISS) and~~ and the Korean Studies Information Service System (KISS)).

Searching other resources

~~The reference lists of review articles and the retrieved articles will be examined to find additional~~ Ongoing studies. ~~Additional trials~~ will be sought in the meta-Register of Controlled Trials (~~m~~ RCT mRCT) (www.controlled-trials.com/mrct), Clinical trials.gov

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

(www.clinicaltrials.gov) and the WHO International Clinical Trials Registry platform (ICTRP) (<http://apps.who.int/trialsearch/>) ~~for all of which list ongoing trials/~~, all of which list ongoing trials. The bibliographic references of all of the included trials will be reviewed to identify other relevant studies. We will also contact the authors of the trial studies and experts in the field.

Search strategy

The strategies for searching The Cochrane Library, MEDLINE, and EMBASE databases are presented in Appendix 1. These strategies will be modified for use with other databases.

Data collection and analysis

Selection of studies

Two of the review’s authors (Son MJ and Kim YH) will independently screen the titles and abstracts of the searched studies, perform the study selection and record their decisions on a standard eligibility form. The arbitrator (Lee MS) will decide upon the study selection when a consensus cannot be reached. The details of selection process will be shown in PRISMA flow diagram (Figure 1).

Inclusion Criteria

- ~~1. In randomised cross-over trials, only the data from the first period will be included to avoid the carry-over effect~~
- ~~2. No language limitation~~
- ~~3. No publication status restriction~~

Formatted: Font: Not Bold, Font color: red

Exclusion Criteria

1. Animal experiments
2. Non-randomised clinical trials
3. Case report/series, news items, and letters
4. Qualitative studies

Data extraction and management

Two of the authors (Son MJ and Kim YH) will independently extract the data using a standard data extraction form and resolve disagreements through discussion before analysis.

When the reported data are insufficient or ambiguous, two of the authors (Kim YE and Lee HW) will contact the corresponding authors of the clinical trials by e-mail or telephone to request additional information or clarification.

Assessment of risk of bias in the included studies

We will independently assess the risk of bias in the eligible studies according to the criteria described in the Cochrane Handbook version 5.1.0, which include random sequence generation, allocation concealment, ~~the blinding of participants and personnel, the blinding of outcome assessment, incomplete outcome data, selective reporting, and other sources of bias~~ ^[22] blinding of participants and personnel, blinding of the outcome assessment, incomplete outcome data, selective reporting, and other sources of bias.²⁸ The quality of the study will be classified as low, unclear or high risk of bias. If necessary, we will contact the authors of eligible trials for clarification. Any differences in opinion will be resolved by discussion or arbitration involving a third author.

Formatted: Font color: Black

Formatted: Font: Not Bold, Font color: Black

Assessment of reporting biases

We will prepare funnel plots to assess the reporting biases if sufficient studies are available (at least 10 trials) [23]. However, funnel plot asymmetry is not the same as publication bias; therefore, we will attempt to distinguish the different possible reasons for the asymmetry, such as small study effects, poor methodological quality and true heterogeneity of the included studies [23-24].

Measurement Measures of the treatment effect

For continuous data, we will use the mean difference (MD) to measure the treatment effect with a 95% confidence intervals (CI) interval (CI). We will convert other forms of data into MDs. In the case of outcome variables with different scales, we will use the standard mean difference (SMD) with a 95% CI. For dichotomous data, we will present the treatment effects as a relative risk (RR) or risk difference (RD) with 95% CIs. WeBased on these results, we will convert other binary data into calculate the RR form associated numbers needed to treat (NNT).

Strategy for missing data

We will conduct intention to treat analyses that include all Unit of the randomised patients. A carry forward of the last observed response analysis issues
Data from parallel-group studies will be used included for meta-analysis. If there are cross-over trials, the first phase of the data will be adopted for patients with analysis.

Managing missing data

~~We will request missing outcome data. We will seek the individual patient data from the original source or the published trial reports when the individual patient authors, whenever possible. If it is not possible to do this, we will only analyse the available data are unavailable.~~

Formatted: Font color: Black

Formatted: Font color: Black

Formatted: Font color: Black

Formatted: Font color: Black

Assessment of heterogeneity

Formatted: Font color: Dark Red

~~If a meta-analysis is possible, we will use the I^2 statistic to quantify the inconsistencies among the included studies. An I^2 value of >50% will be considered indicative of substantial heterogeneity.³¹ If heterogeneity is observed, we will conduct a subgroup analysis to explore its possible causes.³¹~~

Assessment of reporting biases

~~We will prepare funnel plots to assess the reporting biases if sufficient studies are available (at least 10 trials).²⁹ However, funnel plot asymmetry is not the same as publication bias; therefore, we will attempt to distinguish the different possible reasons for the asymmetry, such as small-study effects, poor methodological quality and the true heterogeneity of the included studies.^{29 30}~~

Formatted: Font color: Black

Assessment of heterogeneity

Formatted: Font color: Dark Red

~~If a meta-analysis is possible, we will use the I^2 statistic to quantify the inconsistencies among the included studies. An I^2 value >50% will be considered indicative of substantial heterogeneity [25]. If heterogeneity is observed, we will conduct subgroup analysis to explore the possible causes [25].~~

Formatted: Font: Bold, Font color: Red

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Data synthesis

Data synthesis for comparable trials with comparable outcomes will be performed using Review Manager (RevMan), Version 5.0, for Windows software. ~~The primary meta analyses will be performed using random effects models due to the expected inter trial heterogeneity.2.6.~~

Formatted: Font color: Black

Formatted: Font color: Custom Color(RGB(192,80,77))

Subgroup analysis and investigation of heterogeneity

If ~~there is~~the data are available, a ~~sufficient number of studies,predefined~~ subgroup analysesanalysis will be conducted to assess the heterogeneity ~~between theof~~ different studies, including the following:

1. Laterality of OME: bilateral OME versus unilateral OME
2. Duration of OME: any duration of OME versus persistent OME (lasting for more than two or three months)
3. Duration of treatment
4. Type of herbal medicine
25. Type of control
3. Type of age group.
6. Type of age group (participants aged over 18 years versus children aged two years or more versus children younger than two years)

Sensitivity analysis

~~If an adequate number of studies are available, sensitivity analyses will be performed to determine whether the findings are robust. The following aspects will be considered.~~
Sensitivity analysis will principally be performed as follows:

1. Sample size (e.g., more or less than ~~30~~40 participants in each group)
2. ~~Methodological qualities~~Low risk of bias (e.g., allocation concealment or the blinding of participants/assessors)
3. ~~Analysis related issues (e.g., processes for handling missing data)~~

Discussion

Because no primary data collection will be undertaken, no additional formal ethical assessment or informed consent is required. The systematic review will be published in a peer-reviewed journal. It will also be disseminated electronically and in print. ~~Updates of the~~ The review will be ~~updated, and a GRADE evaluation of the quality of evidence will be~~ conducted to provide ~~a summary~~summaries of the ~~current~~future state of the evidence for the ~~effectiveness~~efficacy of interventions utilising herbal drugs on OME ~~and to~~. The review may guide healthcare ~~practice~~practices and ~~policy~~policies regarding the oral administration of herbal medicines to treat OME.

-

Formatted: Left

Contributors

The protocol was drafted by all authors. It was revised and the final version approved by all authors.

Funding

No external funding was received. ~~Son MJ was supported by Korea Institute of Oriental Medicine (K13380), Kim YH and Lee HW were supported by same institute (K13101) and Lee MS was supported by same institute (K13400).~~

Conflicts of interest

None known

References

1. Mandel EM, Casselbrant ML. Recent developments in the treatment of otitis media with effusion. *Drugs* 2006;**66**(12):1565-76
2. Marchica CL, Pitaro J, Daniel SJ. Recurrent tube insertion for chronic otitis media with effusion in children over 6 years. *International journal of pediatric otorhinolaryngology* 2013;**77**(2):252-5
3. Williamson IG, Dunleavy J, Bain J, Robinson D. The natural history of otitis media with effusion--a three-year study of the incidence and prevalence of abnormal tympanograms in four South West Hampshire infant and first schools. *The Journal of laryngology and otology* 1994;**108**(11):930-4
4. Lee HJ, Park SK, Choi KY, et al. Korean clinical practice guidelines: otitis media in children. *Journal of Korean medical science* 2012;**27**(8):835-48
5. Rosenfeld RM, Culpepper L, Doyle KJ, et al. Clinical practice guideline: Otitis media with effusion. *Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery* 2004;**130**(5 Suppl):S95-118
6. Gunasekera H, Knox S, Morris P, Britt H, McIntyre P, Craig JC. The spectrum and management of otitis media in Australian indigenous and nonindigenous children: a national study. *The Pediatric infectious disease journal* 2007;**26**(8):689-92
7. Paul W, Flint, Bruce H, Haughey, Valerie J, Lund, et al. *Cummings Otolaryngology Head & Neck Surgery* Philadelphia: MOSBY ELSEVIER, 2010.
8. Castagno LA, Lavinsky L. Otitis media in children: seasonal changes and socioeconomic level. *International journal of pediatric otorhinolaryngology* 2002;**62**(2):129-34

9. Eapen RJ, Buss E, Grose JH, Drake AF, Dev M, Hall JW. The development of frequency weighting for speech in children with a history of otitis media with effusion. *Ear and hearing* 2008;**29**(5):718-24

10. Poehling KA, Szilagyi PG, Grijalva CG, et al. Reduction of frequent otitis media and pressure-equalizing tube insertions in children after introduction of pneumococcal conjugate vaccine. *Pediatrics* 2007;**119**(4):707-15

11. Thomas CL, Simpson S, Butler CC, van der Voort JH. Oral or topical nasal steroids for hearing loss associated with otitis media with effusion in children. *The Cochrane database of systematic reviews* 2006(3):CD001935

12. Griffin GH, Flynn C, Bailey RE, Schultz JK. Antihistamines and/or decongestants for otitis media with effusion (OME) in children. *The Cochrane database of systematic reviews* 2006(4):CD003423

13. Gunasekera H, Morris PS, McIntyre P, Craig JC. Management of children with otitis media: a summary of evidence from recent systematic reviews. *Journal of paediatrics and child health* 2009;**45**(10):554-62; quiz 62-3

14. Lous J, Burton MJ, Felding JU, Ovesen T, Rovers MM, Williamson I. Grommets (ventilation tubes) for hearing loss associated with otitis media with effusion in children. *The Cochrane database of systematic reviews* 2005(1):CD001801

15. Rovers MM, Black N, Browning GG, Maw R, Zielhuis GA, Haggard MP. Grommets in otitis media with effusion: an individual patient data meta-analysis. *Archives of disease in childhood* 2005;**90**(5):480-5

16. Barnes PM, Bloom B, Nahin RL. Complementary and alternative medicine use among adults and children: United States, 2007. *National health statistics reports* 2008(12):1-23

17. Ernst E. The efficacy of herbal medicine--an overview. *Fundamental & clinical pharmacology* 2005;**19**(4):405-9
18. Rhee SM, Garg VK, Hershey CO. Use of complementary and alternative medicines by ambulatory patients. *Archives of internal medicine* 2004;**164**(9):1004-9
19. Wen MC, Wei CH, Hu ZQ, et al. Efficacy and tolerability of anti-asthma herbal medicine intervention in adult patients with moderate-severe allergic asthma. *The Journal of allergy and clinical immunology* 2005;**116**(3):517-24
20. Cohen HA, Varsano I, Kahan E, Sarrell EM, Uziel Y. Effectiveness of an herbal preparation containing echinacea, propolis, and vitamin C in preventing respiratory tract infections in children: a randomized, double-blind, placebo-controlled, multicenter study. *Archives of pediatrics & adolescent medicine* 2004;**158**(3):217-21
21. Amirghofran Z, Azadbakht M, Karimi MH. Evaluation of the immunomodulatory effects of five herbal plants. *Journal of ethnopharmacology* 2000;**72**(1-2):167-72
22. Borchers AT, Sakai S, Henderson GL, et al. Shosaiko-to and other Kampo (Japanese herbal) medicines: a review of their immunomodulatory activities. *Journal of ethnopharmacology* 2000;**73**(1-2):1-13
23. Maruyama Y, Hoshida S, Furukawa M, Ito M. Effects of Japanese herbal medicine, Juzen-taiho-to, in otitis-prone children--a preliminary study. *Acta oto-laryngologica* 2009;**129**(1):14-8
24. Xue CC, Hugel HM, Li CG, Story DF. Efficacy, chemistry and pharmacology of chinese herbal medicine for allergic rhinitis. *Current medicinal chemistry* 2004;**11**(11):1403-21
25. Sugiura Y, Ohashi Y, Nakai Y. The herbal medicine, sairei-to, prevents endotoxin-induced otitis media with effusion in the guinea pig. *Acta oto-laryngologica. Supplementum* 1997;**531**:21-33

26. Sugiura Y, Ohashi Y, Nakai Y. The herbal medicine, sairei-to, enhances the mucociliary activity of the tubotympanum in the healthy guinea pig. *Acta oto-laryngologica. Supplementum* 1997;**531**:17-20

27. Levi JR, Brody RM, McKee-Cole K, Pribitkin E, O'Reilly R. Complementary and alternative medicine for pediatric otitis media. *International journal of pediatric otorhinolaryngology* 2013;**77**(6):926-31

28. Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. *Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)*. : The Cochrane Collaboration. Available from www.cochrane-handbook.org, 2011.

29. Sterne JAC, Egger M, Moher D. Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S, eds. *Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)*. : The Cochrane Collaboration. Available from www.cochrane-handbook.org, 2011.

30. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *Bmj* 1997;**315**(7109):629-34

31. Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S, eds. *Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011)*. : The Cochrane Collaboration. Available from www.cochrane-handbook.org, 2011.

Figure legends

Figure 1. Study selection flow diagram

References

Formatted: English (U.K.)

1. Mandel EM, Casselbrant ML. Recent developments in the treatment of otitis media with effusion. *Drugs* 2006;**66**(12):1565-76
2. Marchica CL, Pitaro J, Daniel SJ. Recurrent tube insertion for chronic otitis media with effusion in children over 6 years. *International journal of pediatric otorhinolaryngology* 2013;**77**(2):252-5
3. Williamson IG, Dunleavy J, Bain J, et al. The natural history of otitis media with effusion - a three year study of the incidence and prevalence of abnormal tympanograms in four South West Hampshire infant and first schools. *The Journal of laryngology and otology* 1994;**108**(11):930-4
4. Lee HJ, Park SK, Choi KY, et al. Korean clinical practice guidelines: otitis media in children. *Journal of Korean medical science* 2012;**27**(8):835-48
5. Rosenfeld RM, Culpepper L, Doyle KJ, et al. Clinical practice guideline: Otitis media with effusion. *Otolaryngology - head and neck surgery : official journal of American Academy of Otolaryngology Head and Neck Surgery* 2004;**130**(5 Suppl):S95-118
6. Gunasekera H, Knox S, Morris P, et al. The spectrum and management of otitis media in Australian indigenous and nonindigenous children: a national study. *The Pediatric infectious disease journal* 2007;**26**(8):689-92
7. Castagno LA, Lavinsky L. Otitis media in children: seasonal changes and socioeconomic level. *International journal of pediatric otorhinolaryngology* 2002;**62**(2):129-34

8. Eapen RJ, Buss E, Grose JH, et al. The development of frequency weighting for speech in children with a history of otitis media with effusion. *Ear and hearing* 2008;**29**(5):718-24

9. Poehling KA, Szilagyi PG, Grijalva CG, et al. Reduction of frequent otitis media and pressure-equalizing tube insertions in children after introduction of pneumococcal conjugate vaccine. *Pediatrics* 2007;**119**(4):707-15

10. Thomas CL, Simpson S, Butler CC, et al. Oral or topical nasal steroids for hearing loss associated with otitis media with effusion in children. *The Cochrane database of systematic reviews* 2006(3):CD001935

11. Griffin GH, Flynn C, Bailey RE, et al. Antihistamines and/or decongestants for otitis media with effusion (OME) in children. *The Cochrane database of systematic reviews* 2006(4):CD003423

12. Gunasekera H, Morris PS, McIntyre P, et al. Management of children with otitis media: a summary of evidence from recent systematic reviews. *Journal of paediatrics and child health* 2009;**45**(10):554-62; quiz 62-3

13. Lous J, Burton MJ, Felding JU, et al. Grommets (ventilation tubes) for hearing loss associated with otitis media with effusion in children. *The Cochrane database of systematic reviews* 2005(1):CD001801

14. Rovers MM, Black N, Browning GG, et al. Grommets in otitis media with effusion: an individual patient data meta-analysis. *Archives of disease in childhood* 2005;**90**(5):480-5

15. Barnes PM, Bloom B, Nahin RL. Complementary and alternative medicine use among adults and children: United States, 2007. *National health statistics reports* 2008(12):1-23


16. Borchers AT, Sakai S, Henderson GL, et al. Shosaiko-to and other Kampo (Japanese herbal) medicines: a review of their immunomodulatory activities. *Journal of ethnopharmacology* 2000;**73**(1-2):1-13—
17. Maruyama Y, Hoshida S, Furukawa M, et al. Effects of Japanese herbal medicine, Juzen-taiho-to, in otitis prone children—a preliminary study. *Acta oto-laryngologica* 2009;**129**(1):14-8—
18. Xue CC, Hugel HM, Li CG, et al. Efficacy, chemistry and pharmacology of chinese herbal medicine for allergic rhinitis. *Current medicinal chemistry* 2004;**11**(11):1403-21—
19. Sugiura Y, Ohashi Y, Nakai Y. The herbal medicine, sairei-to, prevents endotoxin-induced otitis media with effusion in the guinea pig. *Acta oto-laryngologica Supplementum* 1997;**531**:21-33—
20. Sugiura Y, Ohashi Y, Nakai Y. The herbal medicine, sairei-to, enhances the mucociliary activity of the tubotympanum in the healthy guinea pig. *Acta oto-laryngologica Supplementum* 1997;**531**:17-20—
21. Levi JR, Brody RM, McKee-Cole K, et al. Complementary and alternative medicine for pediatric otitis media. *International journal of pediatric otorhinolaryngology* 2013;**77**(6):926-31—
22. Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.10 (updated March 2011) The Cochrane Collaboration. Available from www.cochrane-handbook.org, 2011.
23. Sterne JAC, Egger M, Moher D. Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S, eds. *Cochrane Handbook for Systematic Reviews of Interventions*

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

~~Version 510 (updated March 2011) The Cochrane Collaboration. Available from
www.cochrane-handbook.org, 2011.~~

~~24. Egger M, Davey-Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple,
graphical test. *Bmj* 1997;**315**(7109):629-34.~~

~~25. Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta-
analyses. In: Higgins JPT, Green S, eds. *Cochrane Handbook for Systematic Reviews
of Interventions* Version 510 (updated March 2011) The Cochrane Collaboration.
Available from www.cochrane-handbook.org, 2011.~~



91x90mm (300 x 300 DPI)